37 completed, 22 recruiting, 14 not yet recruiting, 13 active not recruiting. 95 Phase 2, 37 Phase 1.
Follow Akeso: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis. AK139, Placebo - Prurigo Nodularis (PN) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-10-01 | 2026-10-20 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps AK139, Placebo - Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Phase 2 | Not yet recruiting | Akeso | 75 | 2026-08-10 | 2026-08-10 |
| A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer AK146D1 for injection, AK112 Injection - Advanced Breast Cancer | Phase 2 | Recruiting | Akeso | 200 | 2026-07-17 | 2026-07-22 |
| A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer AK146D1 for injection, AK112 Injection, Platinum chemotherapy - Advanced Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Recruiting | Akeso | 348 | 2026-07-10 | 2026-07-14 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer AK138D1, Ivonescimab, Carboplatin - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Akeso | 265 | 2026-07-07 | 2026-07-29 |
| A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma AK146D1 for injection, AK112 Injection - Urothelial Carcinoma (UC) | Phase 2 | Not yet recruiting | Akeso | 132 | 2026-06-22 | 2026-06-09 |
| A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer AK138D1, Ivonescimab, treatment of physician's choice - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Akeso | 286 | 2026-06-06 | 2026-04-30 |
| Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer Anlotinib + Cadonilimab, PULSAR - Previously Treated, Advanced, Biliary Tract Cancers | Phase 2 | Active not recruiting | West China Hospital | 26 | 2026-06-03 | 2026-06-09 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis AK139 and placebo, AK139, Placebo - Moderate-to-Severe Atopic Dermatitis | Phase 2 | Not yet recruiting | Akeso | 168 | 2026-04-07 | 2026-03-30 |
| ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive) Ivonescimab, Docetaxel, Standard Treatment group - Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs) | Phase 2 | Recruiting | Second Xiangya Hospital of Central South University | 70 | 2026-03-10 | 2026-03-09 |
| A Study of AK112 in Combination With VG2025 in Colorectal Cancer With Liver Metastases VG2025, AK112 - Colorectal Cancer With Hepatic Metastases | Phase 1 / Phase 2 | Not yet recruiting | Akeso | 72 | 2026-03-02 | 2026-01-21 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis AK139, Placebo - Seasonal Allergic Rhinitis | Phase 2 | Not yet recruiting | Akeso | 111 | 2026-03-02 | 2026-02-27 |
| A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma AK139, Placebo - Asthma | Phase 2 | Not yet recruiting | Akeso | 160 | 2026-02-28 | 2026-02-27 |
| Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) Cadonilimab (AK104), Cisplatin, Paclitaxel - Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | Akeso | 90 | 2025-12-19 | 2025-12-31 |
| A Study of Ivonescimab in First-Line ES-SCLC Ivonescimab, Cadonilimab, AK117 - Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Akeso | 180 | 2025-10-29 | 2025-11-24 |
| SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer radiotherapy, Ivonescimab (20mg/kg Q3W), Non-operative Management - Rectal Cancer, Radiation | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 30 | 2025-10-27 | 2026-08-07 |
| A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer AK112, AK130 - Pancreatic Cancer | Phase 2 | Recruiting | Akeso | 160 | 2025-09-19 | 2026-03-03 |
| AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment AK112 - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Akeso | 60 | 2025-09-05 | 2025-09-08 |
| A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. TT-00420 (tinengotinib), AK104, AK112 - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Akeso | 100 | 2025-07-18 | 2026-03-16 |
Showing 20 of 95. Sign in to see all of them.
Carcinoma, Hepatocellular (7) · Uterine Cervical Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Dermatitis, Atopic (4) · Nasopharyngeal Carcinoma (3) · Ovarian Neoplasms (3) · Asthma (2) · Biliary Tract Neoplasms (2) · Colorectal Neoplasms (2) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Hypercholesterolemia (2) · Leukemia, Myeloid, Acute (2) · Pancreatic Neoplasms (2) · Psoriasis (2) · Rectal Neoplasms (2)
Carboplatin (11) · Paclitaxel (10) · Cisplatin (7) · Docetaxel (7) · Fluorouracil (7) · Oxaliplatin (7) · Capecitabine (5) · Pemetrexed (5) · Azacitidine (4) · Drug Therapy (4) · Gemcitabine (4) · Irinotecan (4) · Injections (3) · Leucovorin (3) · lenvatinib (3)
China (88) · United States (3) · Australia (2) · New Zealand (1)
Li Zhang, MD (3) · Hongzhong Jin, MD (2) · Li Bai, MD (2) · Nong Xu, MD (2) · Ruihua Xu, MD (2) · Shunchang Jiao, MD (2) · Shuyang Zhang, MD (2) · Xiaozhong Chen, MD (2) · Beihua Kong, MD (1) · Caicun Zhou, MD (1) · Changli Wang (1) · Chaosu Hu, MD (1) · Depei Wu, MD (1) · Dingwei Ye, MD (1) · Fei Ma (1)
PMID 35833116, PMID 34327136, PMID 35165764, PMID 36569905, PMID 37593227, PMID 37677918, PMID 37879536, PMID 37942328, PMID 38110665, PMID 38372727, PMID 40114411, PMID 42409321, PMID 42587052